- Home
- BMEA vs GLSI Comparison
BMEA vs GLSI Comparison
Compare BMEA & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- GLSI
- Stock Information
- Founded
- BMEA 2017
- GLSI 2006
- Country
- BMEA United States
- GLSI United States
- Employees
- BMEA N/A
- GLSI N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- BMEA Health Care
- GLSI Health Care
- Exchange
- BMEA Nasdaq
- GLSI Nasdaq
- Market Cap
- BMEA 125.0M
- GLSI 149.5M
- IPO Year
- BMEA 2021
- GLSI 2020
- Fundamental
- Price
- BMEA $2.15
- GLSI $10.91
- Analyst Decision
- BMEA Strong Buy
- GLSI Strong Buy
- Analyst Count
- BMEA 8
- GLSI 1
- Target Price
- BMEA $10.63
- GLSI $39.00
- AVG Volume (30 Days)
- BMEA 658.3K
- GLSI 91.2K
- Earning Date
- BMEA 10-28-2025
- GLSI 11-13-2025
- Dividend Yield
- BMEA N/A
- GLSI N/A
- EPS Growth
- BMEA N/A
- GLSI N/A
- EPS
- BMEA N/A
- GLSI N/A
- Revenue
- BMEA N/A
- GLSI N/A
- Revenue This Year
- BMEA N/A
- GLSI N/A
- Revenue Next Year
- BMEA N/A
- GLSI N/A
- P/E Ratio
- BMEA N/A
- GLSI N/A
- Revenue Growth
- BMEA N/A
- GLSI N/A
- 52 Week Low
- BMEA $1.29
- GLSI $8.06
- 52 Week High
- BMEA $13.07
- GLSI $15.47
- Technical
- Relative Strength Index (RSI)
- BMEA 61.18
- GLSI 48.98
- Support Level
- BMEA $1.98
- GLSI $9.73
- Resistance Level
- BMEA $2.18
- GLSI $10.57
- Average True Range (ATR)
- BMEA 0.12
- GLSI 0.59
- MACD
- BMEA 0.01
- GLSI -0.04
- Stochastic Oscillator
- BMEA 75.76
- GLSI 52.32
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.